{"id":577180,"date":"2026-07-31T13:24:11","date_gmt":"2026-07-31T13:24:11","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/577180\/"},"modified":"2026-07-31T13:24:11","modified_gmt":"2026-07-31T13:24:11","slug":"foldable-synthetic-molecules-could-infiltrate-and-bust-apart-the-toxic-protein-clumps-causing-parkinsons","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/577180\/","title":{"rendered":"Foldable synthetic molecules could infiltrate and bust apart the toxic protein clumps causing Parkinson\u2019s"},"content":{"rendered":"<p>Current therapies for Parkinson\u2019s disease and related conditions <a href=\"https:\/\/www.ninds.nih.gov\/health-information\/disorders\/parkinsons-disease\" rel=\"nofollow noopener\" target=\"_blank\">primarily treat symptoms<\/a> but don\u2019t stop the underlying process causing the disease. <\/p>\n<p><a href=\"https:\/\/doi.org\/10.1101\/cshperspect.a024091\" rel=\"nofollow noopener\" target=\"_blank\">Increasing evidence<\/a> suggests that toxic clumps of proteins called <a href=\"https:\/\/doi.org\/10.1038\/42166\" rel=\"nofollow noopener\" target=\"_blank\">alpha-synuclein<\/a> are among the primary drivers of damage to neurons. <a href=\"https:\/\/scholar.google.com\/citations?user=PMtpDHIAAAAJ&amp;hl=en\" rel=\"nofollow noopener\" target=\"_blank\">My team and I<\/a> developed a synthetic molecule that can block these proteins from clumping and spreading in the brains of mice, ultimately reducing symptoms of disease.<\/p>\n<p>This molecule, <a href=\"https:\/\/doi.org\/10.1126\/scitranslmed.adu1050\" rel=\"nofollow noopener\" target=\"_blank\">called SK-129<\/a>, acts like a molecular brace: It binds to several parts of alpha-synuclein and holds the protein in a shape that makes it less likely to stick to other ones. It binds especially strongly to early forms of these toxic clumps, preventing them from growing and forming new ones.<\/p>\n<p>Why it matters<\/p>\n<p>Beyond SK-129, our research highlights the broader potential of the class of molecules to which it belongs: foldamers. <\/p>\n<p><a href=\"https:\/\/doi.org\/10.1021\/ar960298r\" rel=\"nofollow noopener\" target=\"_blank\">Foldamers<\/a> are laboratory-designed molecules that fold into predictable shapes, much like natural proteins. Because they\u2019re so stable, scientists can tailor them to recognize and bind to specific biological targets. <\/p>\n<p>            <a role=\"button\" aria-label=\"Zoomable image\" aria-haspopup=\"dialog\" href=\"https:\/\/images.theconversation.com\/files\/750993\/original\/file-20260729-71-kopxl4.jpg?ixlib=rb-4.1.1&amp;q=45&amp;auto=format&amp;w=1000&amp;fit=clip\"><img decoding=\"async\" alt=\"Four microscopy images of dark brown spots against speckled pink\" src=\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2026\/07\/file-20260729-71-kopxl4.jpg\" class=\"native-lazy\" loading=\"lazy\"  \/><\/a><\/p>\n<p>              Alpha-synuclein make up the Lewy bodies (darker spots) that form in neurons in Parkinson\u2019s.<br \/>\n              <a class=\"source\" href=\"https:\/\/commons.wikimedia.org\/wiki\/File:Lewy_bodies_(alpha_synuclein_inclusions).svg\" rel=\"nofollow noopener\" target=\"_blank\">Suraj Rajan\/Wikimedia Commons<\/a>, <a class=\"license\" href=\"http:\/\/creativecommons.org\/licenses\/by-sa\/4.0\/\" rel=\"nofollow noopener\" target=\"_blank\">CC BY-SA<\/a><\/p>\n<p>This versatility is particularly important, because many proteins involved in neurodegenerative diseases have long been <a href=\"https:\/\/doi.org\/10.1021\/acs.chemrev.5c00046\" rel=\"nofollow noopener\" target=\"_blank\">considered \u201cundruggable<\/a>.\u201d Unlike other disease proteins with pockets that conventional drugs can bind to, proteins involved in neurodegenerative diseases, such as alpha-synuclein, are highly flexible and lack well-defined binding sites. Synthetic foldamers offer larger surfaces that can engage these difficult targets and disrupt the abnormal protein interactions that lead to toxic aggregation.<\/p>\n<p>Foldamers could <a href=\"https:\/\/doi.org\/10.1038\/s41467-022-29724-4\" rel=\"nofollow noopener\" target=\"_blank\">open new<\/a> <a href=\"https:\/\/doi.org\/10.1126\/scitranslmed.adu1050\" rel=\"nofollow noopener\" target=\"_blank\">treatment avenues<\/a> not only for Parkinson\u2019s disease, but also for other neurodegenerative disorders driven by toxic protein aggregation, including <a href=\"https:\/\/doi.org\/10.1021\/acschemneuro.4c00753\" rel=\"nofollow noopener\" target=\"_blank\">Alzheimer\u2019s disease<\/a> <a href=\"https:\/\/doi.org\/10.1126\/scitranslmed.adu1050\" rel=\"nofollow noopener\" target=\"_blank\">and ALS<\/a>.<\/p>\n<p>What still isn\u2019t known<\/p>\n<p>Although SK-129 showed strong promise in its ability to target Parkinson\u2019s in cell and animal models, we have yet to test its effectiveness in people. <\/p>\n<p>Important questions remain regarding its long-term safety, optimal dosing and how it travels through and interacts with the human body. Additional studies are needed to understand how the molecule works and how to further optimize it to stop or slow Parkinson\u2019s disease from worsening in people.<\/p>\n<p>More broadly, researchers are still working to fully understand how different forms of alpha-synuclein drive neurodegeneration and disease spread. My team is also investigating how selectively targeting these toxic protein clumps influences <a href=\"https:\/\/doi.org\/10.1126\/scitranslmed.adu1050\" rel=\"nofollow noopener\" target=\"_blank\">their spread<\/a>, <a href=\"https:\/\/doi.org\/10.1038\/s41467-024-47980-4\" rel=\"nofollow noopener\" target=\"_blank\">inflammation in the nervous system and brain cell survival<\/a> across different brain regions.<\/p>\n<p>            Researchers are looking for ways to stop toxic clumps of protein from forming in the brain.<\/p>\n<p>What other research is being done<\/p>\n<p>Researchers are actively developing other therapies that target the toxic alpha-synuclein clumps that cause Parkinson\u2019s and related diseases. <\/p>\n<p>These approaches include molecules designed to <a href=\"https:\/\/doi.org\/10.1001\/jamaneurol.2018.1487\" rel=\"nofollow noopener\" target=\"_blank\">clear these protein clumps<\/a> or <a href=\"https:\/\/doi.org\/10.1172\/jci.insight.135633\" rel=\"nofollow noopener\" target=\"_blank\">reduce their production<\/a>, as well as molecules that can <a href=\"https:\/\/doi.org\/10.1038\/s41531-023-00552-7\" rel=\"nofollow noopener\" target=\"_blank\">stop them from aggregating<\/a>. Several of these strategies have <a href=\"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104021\" rel=\"nofollow noopener\" target=\"_blank\">advanced into<\/a> <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04658186\" rel=\"nofollow noopener\" target=\"_blank\">clinical trials<\/a>.<\/p>\n<p>Each major approach to treatment has important limitations. Some struggle to selectively bind to the toxic proteins, while others are unable to penetrate the brain.<\/p>\n<p>Through the collaboration of neuroscientists, biophysicists, clinicians and translational researchers, researchers like me hope to develop new ways to treat diseases that conventional drugs haven\u2019t been able to before.<\/p>\n<p>The <a href=\"https:\/\/theconversation.com\/us\/topics\/research-brief-83231\" rel=\"nofollow noopener\" target=\"_blank\">Research Brief<\/a> is a short take about interesting academic work.<\/p>\n","protected":false},"excerpt":{"rendered":"Current therapies for Parkinson\u2019s disease and related conditions primarily treat symptoms but don\u2019t stop the underlying process causing&hellip;\n","protected":false},"author":2,"featured_media":577181,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[103,61,60],"class_list":["post-577180","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-ie","tag-ireland"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/577180","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=577180"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/577180\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/577181"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=577180"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=577180"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=577180"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}